Pulmonary metastasis in laryngeal squamous cell carcinoma Objective: To identify the factors associated with pulmonary metastasis, such as lymph node positivity, tumour location and histological differentiation in patients with laryngeal squamous cell carcinoma (scc).
INTRODUCTION
Laryngeal squamous cell carcinoma (SCC) is a relatively common tumour, representing 2.4% of diagnosed malignancies (1) . It is the second most common tumour in the head and neck region after thyroid cancer and is mostly seen in middle-aged and elderly males. Laryngeal scc tends to metastasize to the cervical lymph nodes, but hematogenous metastasis is also possible. Although surgery with or without radiation therapy might ensure locoregional control in many, distant metastasis can occur. The reported incidence of distant metastasis is 3-8%, whereas it is 34-57% in post-mortem studies (2, 3) . The high rates of distant metastasis may be due to subclinical metastasis that is present, but not detectable with radiological exams.
Combined chemoradiotherapy and surgical approaches have been used for many years to provide loco-regional control of laryngeal scc. Although locoregional control of the laryngeal scc has improved by successful results of new surgical techniques and advances in radiotherapy and chemotherapy, distant metastases have become increasingly common problems. It is important to consider the risk of distant metastasis in patients with laryngeal scc while developing more effective treatment strategies. Distant metastasis is a direct action of nodular metastasis, but other prognostic factors, including loco-regional control (4-6), primary region (5,7), histological grade (8), local and/or regional extension (5, 6, 9) and immunological capacity (9) contribute to the development of distant metastasis.
Clinical and post mortem studies have reported that the lungs are the most common site of distant metastasis in patients with laryngeal scc (10, 11) . The second most common region is bone (3, 12) , and the liver has been reported as a common metastatic site in autopsy studies (5, 13) . The aim of this study is to review our experience in managing a series of patients with laryngeal scc and identify factors associated with pulmonary metastasis, such as lymph node positivity, primary tumour location and histological differentiation.
MATERIAL AND METHODS
Data from 263 patients diagnosed to be laryngeal scc at our clinic, during 2006-2013 were reviewed retrospectively. Patients who were only diagnosed but not treated in our clinic (n=5), whose histopathologic diagnosis was carcinoma in situ (n=14), whose pulmonary tumour was considered as second primary (n=3), who had loco-regional relapse (n=16) and whose clinical data could not be obtained completely (n=17) were excluded from the study. The remaining 208 patients were included. Results of cervical magnetic resonance imaging (MRI), direct laryngoscopy, direct chest radiography and ultrasound-guided fine-needle aspiration biopsy performed for a suspicious lymph node were provided f r o m t h e p a t i e n t s ' c l i n i c a l r e c o r d s . Fluorodeoxyglucose-positron emission tomographycomputed tomography (PET-CT) and contrastenhanced thoracic CT (14) scans were performed in patients with a risk of distant metastasis (≥3 cm or bilateral lymph node metastasis, ≥6 cm lymph nodes, lower jugular lymph node metastasis). Thoracic CT was performed also on patients with advanced stage laryngeal scc (T3 or T4) and patients who had a suspicious lesion on lung graphy. Bronchoscopy and spirometry test results were recorded. Features such as primary tumour spread, tumour differentiation and the number of positive lymph nodes, were also recorded.
As lungs being the most common organs where cancer spreads in laryngeal scc, we wanted to investigate the rate of pulmonary metastasis in this study design.
Parameters, including histology, grade, TNM stage, interval, initial classification and the number, spread and loco-regional relapse of lesions were used to evaluate lung lesions for metastasis or second primary tumors (15, 16) . The parameters included: 1-Stage III or IV lung lesion or locoregional recurrence. 2-Peripheral location or multiple lesions. 3-The interval between the first admission for the larynx scc and the radiological detection of the lung lesion (shorter than 3 years).
The protocol was submitted to the ethics and research committee, CEP No.565/29.09.'15. Patients who agreed to participate signed the informed consent.
Statistical Analysis
The collected data were analysed using SPSS statistical software (SPSS 13 for Mac, SPSS Inc, Chicago, IL). Frequency and rate values were used as descriptive data. The chi-square or Fisher's test was used to detect differences. Categorical variables were compared using likelihood ratio. A p-value <0.05 was considered significant.
RESULTS

Patient Population
A total of 208 patients (190 males and 18 females; mean age, 60.3 years) were included. The minimum follow-up duration was 2 years (mean 36.7 months). In total, 46% (n=94) (27% (n=56) with N1, 15% (n=31) with N2 and 3% (n=6) with N3 disease) of the patients were radiologically and/or clinically diagnosed with cervical metastasis according to the TNM classification of The American Joint Committee on Cancer for laryngeal cancer staging (17) ( Table-1 ). The pathological result of one patient who had a clinically palpable cervical lymph node was reactive hyperplasia.
About 39% of the patients had supraglottic (n=81), 50% had glottic (n=104), 0% had subglottic (n=1) and 11% had transglottic cancer (n=22) ( Table-2 ). Of these, 25% (n=56) were diagnosed as T1, 27% (n=56) were as T2, 35% (n=72) were as T3, and 11% (n=24) were diagnosed as stage T4 (Table-1) .
The operations performed were cordectomy (n=27, 14%), frontolateral laryngectomy (n=24, 12%), vertical hemilaryngectomy (n=21, 11%), supraglottic horizontal laryngectomy (n=50, 26%), supracricoid laryngectomy (n=29, 15%) and total laryngectomy (n=36, 17%) ( Table-3 ). One hundred eighty seven (90%) patients were operated. Twenty one patients were referred to radiation or chemoradiotherapy for various reasons.
All patients who underwent supraglottic, supracricoid and total laryngectomy (n=115) received primary tumour resection and neck dissection at the same time. Concerning the neck dissection, a selective neck dissection of levels 2-4 was the minimum applied, level 1 (n=3) and level 5 (n=15) node dissections were added according to the perioperative findings, paratracheal nodes (level 6) (n=10, 11%) were also dissected in glottic advanced tumors in which subglottic invasion was detected (n=9) and in the subglottic tumour (n=1). Patients who were pathologically diagnosed with cervical lymph node metastasis (n=93, 44%) underwent postoperative radiotherapy regardless of extracapsular spread or perineural invasion. The patients were evaluated by direct chest radiography every six months and chest CT if needed during the follow-up. Three patients did not attend the follow-up visits and 18% of patients (n=39) were diagnosed to have pulmonary metastasis of squamous cell carcinoma. The mean duration for development of pulmonary metastasis after the primary diagnosis in 34 patients was 11.8 months. Five patients had pulmonary metastases during the diagnostic phase, and referred to chemotherapy and radiotherapy instead of surgery. Nearly all patients (203, 98%) were smokers. The smoking rate for the smokers was 10-150 pack-years (mean, 56 pack-years).
Various treatments (chemotherapy/radiotherapy/ radiosurgery/metastectomy) were used to treat patients with pulmonary metastasis after laryngeal surgery.
Tumour Location, Neck Lymph Positivity and Staging and Tumour Differentiation
Most pulmonary metastasis rates were observed in patients with transglottic (50%) and supraglottic tumors (21%), respectively. The pulmonary metastatis rate was significantly higher in patients with transglottic tumors than those with tumors in other regions (p=0.000). The pulmonary metastasis rate was significantly lower in patients with glottic tumors than those with tumors in other regions (p= 0.003) ( Table-4) .
Pulmonary metastases were seen more frequently in patients with positive cervical lymph nodes compared to those with negative cervical lymph nodes (p<0.05) ( Table-4 ). The pulmonary metastasis rate was also significantly higher in patients with cervical stage N2-N3 compared with those with patients with cervical stage N1 (p<0.05) ( Table-4 ).
The pulmonary metastasis rate was 8% in patients with N0 cervical lymph nodes, and 33% in patients with cervical metastasis (p=0.000) ( Table-4) .
Pulmonary metastasis increased significantly in cases with histologically poorly differentiated tumors (p=0.001) ( Table-4 ).
DISCUSSION
The relationship between lymph node positivity and distant metastasis is well recognized. In our study, we found that pulmonary metastatis rate was significantly higher among lymph node-positive patients compared to lymph node-negative patients, which is compatible with previous reports (6, 8) .
The clinically identified distant metastasis rates in patients with head-neck cancers (HNC) was reported to be 4-25% and distant metastasis is usually observed after regional metastasis and nodal metastasis increases the risk approximately by three times (11, 18) .
Although a relationship between distant metastasis and T stage was reported previously (6, 18) , the relationship between distant metastasis and N stage is better understood (6, 8) . Patients with more than one palpable lymph node carry a higher risk of distant metastasis than those with one involved lymph node (3, 5, 19) . High nodal disease stage, the number of lymph node metastases and involvement of low level lymph nodes (level 4, 5) are closely related to distant metastasis and the risk of distant metastasis increases up to 50% when three or more lymph nodes are involved (12) . In our study, the pulmonary metastasis rate in patients with N2-N3 stage cervical lymph nodes was significantly higher than in patients with N1 stage lymph nodes (p=0.000). However, Kotwall et al. (13) determined that patients with N2 and N3 cervical lymph node involvement didn't have an increased risk for distant metastasis compared to those with N0 stage disease and that tumor staging rather than lymph node staging was more effective in determining the distant metastasis rate. Other nodal involvement features, such as high or low level of lymph node involvement and extracapsular spread were shown to significantly affect the rate of distant metastasis (20, 21) . The time between diagnosis and identification of a distant metastasis is 9-12 months (8). Merine et al. (6) reported that clinically identifiable distant metastases are observed in 80% of patients within 2 years after diagnosis. In our study, distant metastasis was observed approxiamately 11.8 months after primary diagnosis. A limited number of studies have detected distant metastasis at diagnosis. The distant metastasis rate in metastatic group was 12% (n=5) at diagnosis.
Various risk factors are associated with the development of distant metastasis, one of the most common risk factor involved is the primary site (22, 23) . Bhatia et al. (3) demonstrated that the risk for distant metastasis is the highest in patients with supraglottic laryngeal cancer (9.1%). In another study, tumors located in the hypopharyngeal and supraglottic areas were considered to have the highest risk for distant metastasis (22) . However, many studies have reported that tumour location is not a risk factor for development of distant metastasis (4, 9) . In our study, the pulmonary metastasis rate in patients with transglottic tumors was significantly higher than in patients with tumors in other regions. The pulmonary metastasis rate of the patients with glottic tumors was significantly lower than the patients with tumors in other locations. Unlike other studies, we found no difference in pulmonary metastasis rate of the patients with supraglottic tumors, comparing the rate of the patients with glottic tumors.
Some studies have reported that loco-regional relapse in head and neck SCC increases the risk of distant metastasis (6, 8) , and that failure to maintain loco-regional disease control is a major factor associated with an increased risk for distant metastasis (5, 6) . Leon et al. (22) reported that only 5% of patients with loco-regional control have distant metastasis, whereas 18% of patients without loco-regional control have distant metastasis. None of our patients had locoregional relapse, and distant metastasis was detected in 39 patients (18%) despite loco-regional control.
Fortin et al. (24) reported that tumor histological grade is associated with distant metastasis rates in a multivariate study involving patients with HNC. It is thought that poorly differentiated cancers are more prone to distant metastasis than well-differentiated cancers (8, 13) . In our study, the pulmonary metastasis rate increased significantly as tumor histological differentiation decreased. However, other studies have reported no association between histological grade and the risk for distant metastasis (25, 26) .
As distant metastasis negatively affects the disease course, one of the main purpose of treatment should be to prevent it. Therefore, the significance of following up pulmonary metastasis in patients with HNC should be emphasised. However, the best pulmonary follow-up strategy has not been identified. Annual CT scans are suggested for the first 2 years of follow-up in patients with high-risk HNC (27) .
The main limitation of our study was the relatively small size of our series. This was a single-institution study. Further randomized, prospective, controlled trials on larger series are necessary for making more precise interpretations.
We observed that patients with tumors which were less differentiated or transglottic or metastatic to the cervical lymph nodes had an increased rate of pulmonary metastasis. Patients with these features should be monitored carefully and followed up closely for pulmonary metastasis. Unfortunately, detecting distant metastasis earlier does not always provide recovery, as it indicates incurable disease and mostly they are managed with intent to palliation (28) .
Disclosure of potential conflict of interest:
The authors have declared that they have no conflict of interest.
